Thromboembolism

1. High-Yield Summary

Venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), represents one of the most critical and preventable complications in musculoskeletal medicine and orthopaedic surgery:

• Virchow’s Triad in Musculoskeletal Surgery: Surgical dissection, limb positioning, mechanical vessel deformation, exothermic cement curing, and reaming-induced marrow intravasation simultaneously trigger severe venous stasis, local endothelial injury, and profound systemic hypercoagulability.
• Historical vs. Contemporary Incidence: In the absence of thromboprophylaxis, historical objective screening demonstrated DVT rates of 40% to 60% following total hip arthroplasty (THA), 50% to 70% following total knee arthroplasty (TKA), and 40% to 60% following hip fracture surgery, with fatal PE rates of 1% to 5%. Modern multimodal protocols have lowered symptomatic DVT to 0.5% to 2.0% and fatal PE to less than 0.1%.
• Multimodal Prophylaxis Architecture: Effective prevention requires combining early post-anesthetic mobilization, uninterrupted mechanical prophylaxis (bilateral intermittent pneumatic compression [IPC] devices), and risk-stratified chemoprophylaxis. No single pharmacological agent replaces the physiological calf muscle pump.
• Evidence-Based Chemoprophylaxis Hierarchy: Landmark trials establish distinct roles: the EPCAT II trial validated aspirin (81 mg daily) as noninferior to rivaroxaban after an initial 5-day post-op course in elective THA and TKA. In extremity fracture trauma, the PREVENT CLOT trial established that aspirin (81 mg twice daily) is noninferior to low-molecular-weight heparin (enoxaparin 30 mg twice daily) for 90-day all-cause mortality. Conversely, CRISTAL demonstrated that enoxaparin initiated on postoperative day 1 is superior to aspirin for reducing 90-day symptomatic VTE (primarily distal DVT) after knee replacement.
• The Bleeding-Infection Paradox & Neuraxial Safety: Aggressive anticoagulation significantly escalates surgical site wound drainage and hematoma formation, which directly multiplies the odds of periprosthetic joint infection (PJI). Timing of chemoprophylaxis must strictly comply with American Society of Regional Anesthesia (ASRA) guidelines to prevent catastrophic epidural hematoma.

2. Anatomy & Pathophysiologic Topography

Venous Architecture of the Lower Extremity & Pelvis

The lower extremity venous system is anatomically compartmentalized into superficial veins, deep veins, and interconnecting perforating veins equipped with unidirectional bicuspid valves directing blood inward and proximally toward the heart:

• Distal Deep Veins (Calf Sinuses): Comprise paired venae comitantes accompanying corresponding arteries: anterior tibial veins (draining the dorsum of the foot and anterior compartment), posterior tibial veins (draining the plantar foot and deep posterior compartment), and peroneal veins (draining the lateral compartment). The soleal and gastrocnemius venous plexuses form massive intramuscular blood reservoirs (soleal sinuses) where low-shear static pooling predominantly seeds primary microthrombi.
• Popliteal & Femoral Venous Axis: The anterior tibial, posterior tibial, and peroneal veins unite at the inferior border of the popliteus muscle to form the popliteal vein. Traversing the adductor hiatus (Hunter’s canal), the popliteal vein becomes the femoral vein (historically termed the superficial femoral vein, though strictly a component of the deep system). In the proximal thigh, the femoral vein unites with the deep femoral vein (profunda femoris) within the femoral triangle to establish the common femoral vein (CFV).
• Pelvic & Caval Conduit: The common femoral vein passes deep to the inguinal ligament, medial to the common femoral artery, to become the external iliac vein. Deep in the true pelvis, the external and internal iliac veins unite anterior to the sacroiliac joint to form the common iliac vein. At the level of the fifth lumbar vertebra, the right and left common iliac veins coalesce to form the inferior vena cava (IVC), which courses cephalad in the retroperitoneum along the right anterior margin of the lumbar spine.

Distal vs. Proximal DVT: Hemodynamic & Embolic Determinants

The anatomical location of a deep venous thrombus dictates its natural history, risk of embolization, and therapeutic threshold:

• Distal (Calf) DVT: Involves veins distal to the popliteal trifurcation (anterior tibial, posterior tibial, peroneal, or muscular sinus veins). Thrombi in this low-pressure vascular bed are typically small, tightly adherent, and carry a low risk of immediate pulmonary embolization (<1% risk of fatal PE). However, approximately 15% to 20% of untreated calf thrombi propagate proximally into the popliteal vein, where embolic potential escalates dramatically.
• Proximal DVT: Involves the popliteal vein, femoral vein, common femoral vein, or iliac veins. Proximal thrombi form in high-volume, wide-caliber conduits and exhibit large, non-adherent, free-floating tail segments. Without therapeutic intervention, approximately 50% of proximal lower extremity deep venous thrombi embolize to the pulmonary arterial circulation, with high rates of obstructive hemodynamic collapse and mortality.

Surgical Danger Zones & Venous Vulnerabilities in Orthopaedics

Specific orthopaedic exposures and surgical maneuvers place adjacent venous structures at direct risk of mechanical trauma, focal occlusion, or traction injury:

• Acetabular Exposure in THA: Anterior acetabular retractors placed over the anterior pelvic rim can directly compress, kink, or lacerate the femoral vein and femoral artery. Retractors placed in the inferior obturator notch can lacerate the obturator venous plexus. Subperiosteal placement directly onto bone without soft-tissue trapping is mandatory.
• Femoral Preparation & Dislocation in THA: Extreme adduction, flexion, and external rotation of the operative limb during femoral canal reaming and broaching produces profound torsion and functional occlusion of the common femoral vein, causing acute downstream venous stasis.
• Total Knee Arthroplasty (Popliteal Fossa): The popliteal neurovascular bundle lies immediately adjacent to the posterior joint capsule in the midline. During proximal tibial resection, aggressive posterior retractor placement or uncalibrated oscillating saw excursion through the posterior cortex risks direct laceration or pseudoaneurysm of the popliteal vein and artery. Knee flexion shifts the popliteal vessels posteriorly away from the tibial rim, creating a critical safety margin.
• Pelvic & Acetabular Approaches (Ilioinguinal / Stoppa): The middle window of the ilioinguinal approach requires formal circumferential dissection and mobilization of the external iliac vein and artery. In anterior intrapelvic (modified Stoppa) approaches, the corona mortis (an aberrant venous or arterial anastomosis between the external iliac and obturator systems crossing the superior pubic ramus 4 to 6 cm lateral to the symphysis pubis) is encountered and must be proactively identified, clipped, or cauterized to avoid brisk retroperitoneal hemorrhage.

3. Pathogenesis & Hematologic Mechanisms

Virchow’s Triad in the Orthopaedic Setting

The pathogenesis of venous thromboembolism in musculoskeletal surgery represents the classic biological manifestation of Virchow’s Triad, operating at maximal physiological intensity:

• Venous Stasis: Eliminates laminar blood flow and prevents clearance of activated coagulation factors. Factors include intraoperative pharmacological muscle relaxation, intraoperative limb traction and extreme positioning (kinking major vessels), pneumatic tourniquet application (inducing complete circulatory standstill in the extremity), and postoperative immobility with loss of muscular pumping action.
• Endothelial Injury: Mechanical stretch, surgical dissection, retractor pressure, and thermal injury disrupt the protective endothelial glycocalyx. Polymerization of polymethylmethacrylate (PMMA) bone cement produces exothermic temperatures reaching 70°C to 80°C at the bone-cement interface, inducing local thermal denudation of intramedullary and periosteal venules. Denuded subendothelial matrix exposes collagen and von Willebrand factor, triggering immediate platelet adhesion, glycoprotein IIb/IIIa activation, and aggregation.
• Systemic Hypercoagulability: Opening and reaming of the intramedullary canals of the femur and tibia shears extensive venous sinusoids, dumping abundant tissue factor (thromboplastin, factor III) into the systemic circulation. Tissue factor complexes with activated factor VII (VIIa) to trigger the extrinsic coagulation pathway, generating explosive thrombin bursts (factor IIa) and cleaving fibrinogen into cross-linked fibrin networks. Concurrently, major surgical trauma induces an acute-phase reactant state that markedly elevates Plasminogen Activator Inhibitor-1 (PAI-1), shutting down endogenous fibrinolysis for 5 to 7 days postoperatively.

Intramedullary Pressurization & Embolic Showers

Intramedullary instrumentation during cemented or uncemented arthroplasty, intramedullary nailing, and long-bone reaming creates acute canal pressures exceeding 300 to 1,000 mmHg. When canal pressure exceeds venous sinus pressure, bone marrow contents, fat droplets, PMMA monomers, and microthrombi are forced into damaged transcortical venous channels, creating immediate microembolic showers to the pulmonary circulation (Bone Cement Implantation Syndrome [BCIS] / Fat Embolism Syndrome [FES]). These microemboli provoke pulmonary vasoconstriction, acute right ventricular strain, and secondary local platelet aggregation.

4. Natural History & Epidemiology

Epidemiological Milestones in Musculoskeletal Surgery

Orthopaedic surgery historically carried the highest risk of postoperative venous thromboembolic disease of any surgical specialty. In historical prospective screening trials prior to the routine implementation of pharmacoprophylaxis and rapid rehabilitation protocols, total DVT rates were documented at 40% to 60% after total hip arthroplasty, 50% to 70% after total knee arthroplasty, and up to 60% after femoral neck or acetabular fracture repair. Fatal pulmonary embolism occurred in 1.5% to 5.0% of elective arthroplasty patients.

Modern clinical practice incorporating routine multimodal prophylaxis, tranexamic acid, neuraxial anesthesia, rapid same-day mobilization, and standardized chemoprophylaxis has transformed these outcomes. In contemporary large-scale registries, the 90-day incidence of symptomatic DVT following elective primary THA and TKA is 0.5% to 1.8%, while symptomatic PE occurs in 0.3% to 0.7%, and fatal PE is reduced to less than 0.05% to 0.1%.

Chronic Long-Term Sequelae: Post-Thrombotic Syndrome & CTEPH

The burden of venous thromboembolism extends far beyond the acute perioperative episode, generating substantial chronic morbidity:

• Post-Thrombotic Syndrome (PTS): Develops in 20% to 50% of patients within 1 to 2 years following an episode of symptomatic proximal DVT. Incomplete thrombus recanalization and valvular destruction cause chronic ambulatory venous hypertension, persistent lower extremity edema, intractable aching pain, hyperpigmentation, lipodermatosclerosis, and recalcitrant venous stasis ulceration (quantified by the Villalta scale).
• Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Develops in 1% to 4% of patients surviving an acute pulmonary embolism within 24 months. Failure of complete mechanical thrombus resolution results in organized fibrotic obstruction of pulmonary arterial branches, microvascular remodeling, progressive elevation of pulmonary vascular resistance, right ventricular hypertrophy, cor pulmonale, and progressive right-sided heart failure.

5. Clinical Presentation

History & Symptom Stratification

The clinical presentation of VTE ranges from completely silent thrombosis to catastrophic hemodynamic collapse. High clinical suspicion is required:

• Deep Vein Thrombosis: Patients report progressive unilateral calf or thigh tightness, dull persistent aching, dependent fullness, and pain aggravated by weight-bearing. More than 60% of deep venous thrombi confirmed on screening venography are entirely asymptomatic during the early postoperative hospitalization.
• Pulmonary Embolism: The classic triad of pleuritic chest pain, dyspnea, and hemoptysis is present in less than 20% of patients. Sudden unexplained dyspnea is the most common presenting symptom (>80%). Other symptoms include tachypnea, substernal tightness, apprehension, dizziness, presyncope, and acute syncope (a hallmark of massive saddle embolus obstructing right ventricular outflow).

Physical Examination & Provocative Maneuvers

Physical examination findings must be documented systematically, recognizing the limited sensitivity and specificity of individual clinical signs:

• Asymmetric Calf Circumference: Measured 10 cm distal to the tibial tuberosity. A discrepancy of >3 cm compared to the asymptomatic contralateral extremity strongly suggests acute deep venous obstruction [Sensitivity 65%, Specificity 70%].
• Venous Palpation & Tenderness: Localized tenderness along the anatomic course of the deep veins (popliteal fossa, medial gastrocnemius, Hunter’s canal, or femoral triangle). Palpation may reveal a firm, tender, indurated venous “cord.”
• Homan’s Sign: Passive ankle dorsiflexion eliciting pain in the posterior calf. Demonstrates poor diagnostic utility [Sensitivity 33%, Specificity 55%]. Forceful dorsiflexion is contraindicated because of the theoretical risk of dislodging a non-adherent, freshly formed thrombus.
• Phlegmasia Alba Dolens & Cerulea Dolens: Phlegmasia alba dolens (“milk leg”) presents as severe edema, pallor, and cool skin caused by massive iliofemoral venous thrombosis triggering secondary arterial vasospasm. Progression to phlegmasia cerulea dolens represents a catastrophic limb-threatening emergency characterized by cyanosis, tense edema, rest pain, bullae, and loss of distal arterial pulses due to extreme compartment hypertension, carrying high risk of venous gangrene and amputation.
• Cardiopulmonary Signs in PE: Tachypnea (>20 breaths/min, >70% of cases), resting tachycardia (>100 bpm), hypoxemia (low pulse oximetry saturation refractory to oxygen), accentuated pulmonic component of the second heart sound (P2), tricuspid regurgitant murmur, elevated jugular venous pressure, and acute systemic hypotension (systolic BP 40 mmHg).

6. Imaging and Diagnostic Studies

The D-Dimer Trap in the Postoperative Orthopaedic Patient

Serum D-dimer testing (fibrin degradation product) has high sensitivity (>98%) and high negative predictive value in unselected outpatient populations, reliably excluding VTE in patients with low pre-test probability. However, in the postoperative orthopaedic patient, physiological fibrin formation and lysis at the operative site produces marked, prolonged D-dimer elevations for 4 to 8 weeks after surgery. Therefore, a positive D-dimer test has virtually zero positive predictive value in the acute postoperative setting and should not be ordered because it invariably triggers unnecessary advanced imaging.

Compression Duplex Ultrasonography (CUS)

Compression duplex ultrasonography is the first-line gold standard imaging modality for suspected lower extremity DVT:

• Diagnostic Criterion: The primary and definitive diagnostic criterion is the complete inability to compress the venous lumen under gentle, direct ultrasound probe pressure in the transverse plane.
• Color & Spectral Doppler Findings: Direct visualization of intraluminal hypoechoic or hyperechoic thrombus, absence of spontaneous color flow, loss of normal respiratory phasicity, and blunted or absent flow augmentation upon manual distal calf squeezing.
• Diagnostic Accuracy: For proximal DVT (popliteal to common femoral veins), duplex ultrasound exhibits sensitivity >95% and specificity >98%. For isolated calf vein thrombosis, sensitivity drops to 50% to 70% due to multiple tortuous branches, severe postoperative soft-tissue edema, and surgical dressings.

Computed Tomography Pulmonary Angiography (CTPA)

CTPA is the definitive gold standard for the diagnosis of acute pulmonary embolism. A rapid intravenous bolus of iodinated contrast is timed to opacify the pulmonary arterial trunk. Directly identifies intraluminal filling defects as low-attenuation areas surrounded by contrast or complete vessel cutoff. Evaluates clot burden (saddle, lobar, segmental, subsegmental) and provides quantitative signs of acute right ventricular strain: right ventricular to left ventricular diameter ratio (RV/LV ratio) >0.9 on axial four-chamber views, flattening or leftward bowing of the interventricular septum, and reflux of contrast into the inferior vena cava.

Ventilation-Perfusion (V/Q) Scintigraphy

Indicated when CTPA is contraindicated because of severe renal impairment (estimated GFR 75% of a segment) mismatched segmental perfusion defects with normal ventilation, carrying a >85% positive predictive value for acute PE.

Transthoracic Echocardiography (TTE) in Hemodynamic Instability

In critically ill, hemodynamically unstable patients unable to tolerate transfer to the CT scanner, bedside TTE rapidly detects acute cor pulmonale: McConnell’s sign (hyperdynamic apex with regional akinesia of the right ventricular free wall, highly specific for acute PE), right ventricular dilatation (RV end-diastolic diameter exceeding LV diameter), tricuspid regurgitant jet velocity >2.8 m/s, and pulmonary arterial systolic hypertension.

7. Classification & Risk Stratification

Validated clinical prediction rules guide pre-test probability assessment, selecting appropriate diagnostic pathways and tailoring the intensity of thromboprophylaxis:

8. Treatment & Prevention Strategy

Multimodal Prophylaxis Architecture

Modern orthopaedic thromboprophylaxis is multimodal, integrating rapid mobilization, mechanical compression, and tailored chemoprophylaxis:

• Mechanical Compression Devices: Intermittent pneumatic compression (IPC) devices should be fitted preoperatively or immediately upon arrival in the post-anesthesia care unit and worn continuously throughout the hospital stay. Mechanical compression empties stagnant venous blood from the deep calf sinuses, reduces venous distention, and stimulates endothelial release of tissue plasminogen activator (tPA). IPC monotherapy is reserved for patients at extreme bleeding risk where chemoprophylaxis is strictly contraindicated.
• Early Postoperative Ambulation: Initiating weight-bearing rehabilitation within 4 to 8 hours postoperatively restores active calf muscle pump hemodynamics, substantially reducing the risk of stasis-induced thrombus formation.

Chemoprophylactic Pharmacotherapy & Dosing Protocols

Selection of chemical thromboprophylaxis depends on the surgical procedure, baseline patient risk factors, and bleeding tolerance:

• Aspirin (Acetylsalicylic Acid, ASA): Irreversibly acetylates platelet cyclooxygenase-1 (COX-1), suppressing thromboxane A2 production. Dosed at 81 mg twice daily or 100 mg once daily. In elective primary THA and TKA, the EPCAT II trial established that after an initial 5-day course of direct oral anticoagulation (rivaroxaban), step-down to aspirin 81 mg daily was noninferior in preventing symptomatic VTE. In musculoskeletal trauma, the landmark PREVENT CLOT trial demonstrated that aspirin 81 mg twice daily was noninferior to enoxaparin 30 mg twice daily for all-cause mortality and PE. Aspirin is the preferred agent in standard-risk elective joint arthroplasty patients because of its minimal bleeding risk and oral convenience.
• Low-Molecular-Weight Heparin (LMWH, Enoxaparin, Dalteparin): Potentiates antithrombin III, selectively inactivating factor Xa with lesser anti-IIa activity. Standard prophylactic dosing is enoxaparin 30 mg subcutaneously every 12 hours (standard North American trauma dosing) or 40 mg subcutaneously once daily (standard European and arthroplasty dosing). Dalteparin is dosed at 5,000 units once daily. Standard of care in high-risk patients, pelvic/acetabular fractures, and polytrauma. Initiated 12 to 24 hours postoperatively. Dose adjustment is required when creatinine clearance is <30 mL/min.
• Direct Oral Factor Xa Inhibitors (DOACs, Rivaroxaban, Apixaban): Orally active direct factor Xa inhibitors. Rivaroxaban is dosed at 10 mg orally once daily, initiated 6 to 10 hours postoperatively. Apixaban is dosed at 2.5 mg orally twice daily, initiated 12 to 24 hours postoperatively. The RECORD and ADVANCE trial series established that direct factor Xa inhibitors significantly reduce total venographic DVT compared to enoxaparin, with oral administration requiring no routine laboratory monitoring.
• Prophylaxis Duration Guidelines: Following elective total knee arthroplasty, chemoprophylaxis is maintained for 10 to 14 days. Following elective total hip arthroplasty and hip fracture surgery, extended prophylaxis for a minimum of 30 to 35 days is strongly recommended by both the American Academy of Orthopaedic Surgeons (AAOS) and American College of Chest Physicians (ACCP).

Therapeutic Anticoagulation for Confirmed Acute VTE

When acute deep vein thrombosis or pulmonary embolism is objectively diagnosed, therapeutic-intensity anticoagulation must be initiated promptly:

• Hemodynamically Stable DVT / Non-Massive PE: First-line therapy utilizes direct oral anticoagulants: apixaban (10 mg PO BID for 7 days, followed by 5 mg PO BID) or rivaroxaban (15 mg PO BID with food for 21 days, followed by 20 mg PO daily). Alternatively, weight-based therapeutic LMWH (enoxaparin 1 mg/kg SC q12h or 1.5 mg/kg SC q24h) is administered. Therapeutic duration for a provoked surgical VTE is a minimum of 3 months.
• Hemodynamically Unstable / Massive PE: In acute PE presenting with sustained hypotension (systolic BP <90 mmHg), cardiogenic shock, or severe RV collapse, immediate systemic thrombolysis (alteplase [tPA] 100 mg IV infusion over 2 hours) is indicated if surgical bleeding risk permits. In the immediate postoperative window (<10 to 14 days from major arthroplasty), systemic thrombolysis carries catastrophic risks of fatal surgical site or retroperitoneal hemorrhage. Emergency catheter-directed suction thrombectomy, catheter-directed low-dose thrombolysis, or open surgical pulmonary embolectomy under cardiopulmonary bypass must be mobilized.

Interventional & Surgical Indications: IVC Filters & Thrombectomy

Mechanical interventions and vena caval filtration are indicated in specific high-risk scenarios:

• Inferior Vena Cava (IVC) Filters: Explicit indications: (1) Objectively confirmed acute proximal DVT or PE in a patient with an absolute contraindication to therapeutic anticoagulation (e.g., active major surgical hemorrhage, acute gastrointestinal ulcer, scheduled urgent spinal or intracranial surgery); (2) Objectively confirmed recurrent VTE despite proven therapeutic anticoagulation; (3) Massive PE with severe cardiopulmonary compromise where a subsequent small embolus would be fatal. Retrievable IVC filters should be systematically tracked and removed as soon as the bleeding risk subsides (ideally within 3 to 6 months) to avoid long-term filter tilt, caval wall penetration, strut fracture, and caval thrombosis.
• Percutaneous Catheter-Directed Thrombectomy: Indicated for extensive acute iliofemoral DVT causing phlegmasia cerulea dolens or severe compartment syndrome refractory to elevation. Mechanical aspiration rapidly restores venous outflow, preserves microvascular perfusion, and salvages limb viability.

Neuraxial Anesthesia Guidelines (ASRA Protocols)

To prevent catastrophic compressive spinal epidural hematoma resulting in irreversible paraplegia, timing between anticoagulant administration and neuraxial puncture or catheter manipulation must adhere strictly to American Society of Regional Anesthesia (ASRA) guidelines:

• Prophylactic LMWH (Enoxaparin 40 mg daily): Delay spinal/epidural needle insertion or catheter removal for at least 12 hours following the last dose. Wait at least 4 hours after catheter removal before administering the subsequent dose.
• Therapeutic LMWH (Enoxaparin 1 mg/kg q12h): Delay neuraxial needle puncture or catheter removal for a minimum of 24 hours following the last dose.
• Direct Oral Anticoagulants (Rivaroxaban, Apixaban): Withhold rivaroxaban and apixaban for at least 72 hours prior to neuraxial needle placement or epidural catheter manipulation. Wait at least 6 hours following catheter removal before restarting oral therapy.
• Aspirin Monotherapy: ASRA considers low-dose aspirin monotherapy safe for spinal and epidural puncture without discontinuation, provided no other concurrent antiplatelet agents (clopidogrel, ticagrelor) or anticoagulants are present.

9. Outcomes & Long-Term Prognosis

The long-term prognosis following postoperative venous thromboembolism is governed by the provocation source, rapidity of therapeutic initiation, and development of chronic venous hypertension:

• Thromboembolism Recurrence Rates: In provoked VTE secondary to major orthopaedic surgery, completion of a 3-month course of therapeutic anticoagulation carries a low recurrence rate (<2% to 3% at 1 year, and <5% at 5 years). By contrast, unprovoked VTE carries a 1-year recurrence rate of approximately 10% and a 5-year recurrence rate approaching 30%, mandating indefinite secondary prevention.
• Post-Thrombotic Syndrome Burden: In patients experiencing symptomatic proximal DVT, post-thrombotic syndrome develops in 20% to 50% within 2 years. Patients with severe PTS experience chronic disability, inability to return to athletic activities, and recurrent venous ulceration requiring long-term compression therapy.
• Bleeding Morbidity vs. Periprosthetic Joint Infection: Major bleeding requiring surgical re-exploration occurs in 0.5% to 1.8% of patients receiving potent anticoagulants (LMWH, DOACs). Persistent surgical wound drainage exceeding 72 hours postoperatively directly increases the risk of deep periprosthetic joint infection (odds ratio 3.5 to 5.2), necessitating surgical irrigation, debridement, and potential two-stage revision arthroplasty.

10. Complications

Complications associated with venous thromboembolism and its pharmacological management fall into three primary categories:

11. Pearls and Pitfalls

• The “Wound-Infection Rule”: In major joint arthroplasty, the surgical wound is paramount. Persistent wound drainage past postoperative day 3 is an infection emergency. Continuing potent chemoprophylaxis across an actively leaking arthroplasty wound significantly increases the risk of deep periprosthetic infection. If drainage persists, step down chemoprophylaxis to low-dose aspirin, maintain uninterrupted bilateral mechanical compression, and prepare for formal operative irrigation and debridement if drainage fails to stop.
• Avoid the D-Dimer Test in Inpatients: Never order a serum D-dimer test on a patient who has undergone orthopaedic surgery within the preceding 6 weeks. Major surgical trauma universally elevates fibrin degradation products. A positive D-dimer test adds zero diagnostic value and forces patients into unnecessary advanced contrast imaging. Proceed directly to compression duplex ultrasonography or CTPA based on validated Wells pre-test probability.
• Stratify Distal vs. Proximal Thrombi: Isolated, asymptomatic distal calf vein thrombosis (soleal, gastrocnemius, peroneal veins) carries a low risk of pulmonary embolization. In patients with high bleeding risk, routine full-dose therapeutic anticoagulation is unnecessary; instead, perform serial compression duplex ultrasonography at 1 and 2 weeks to monitor for proximal propagation, treating only if extension into the popliteal vein is identified.
• ASRA Timing Discipline: Never compromise on ASRA withholding intervals. Resuming a direct oral factor Xa inhibitor or LMWH prematurely in a patient with an indwelling epidural catheter or immediately after difficult spinal needle puncture can cause an epidural hematoma that results in permanent paraplegia.
• The “Forgotten Filter” Trap: Placing an IVC filter without an automated registry and explicit retrieval timeline is a critical management pitfall. Non-retrieved temporary filters demonstrate long-term caval occlusion rates exceeding 15% to 20%, filter strut fracture, and secondary chronic bilateral lower extremity venous ulceration.
• Screening vs. Diagnostic Doppler: Do not perform routine surveillance duplex ultrasonography on asymptomatic post-arthroplasty patients. Screening identifies non-propagating subclinical microthrombi that resolve spontaneously. Overtreating these incidental findings with therapeutic anticoagulation triples the risk of major surgical site bleeding and reoperation without reducing symptomatic PE or mortality.

12. Controversy & Evolving Evidence

Aspirin Monotherapy vs. Potent Anticoagulation: The Arthroplasty Debate

The role of aspirin as primary chemoprophylaxis in elective joint arthroplasty has been a subject of intense clinical debate, shaped by conflicting landmark multicenter randomized trials:

• EPCAT II Trial Findings: The EPCAT II trial (Anderson et al., NEJM 2018) evaluated 3,424 patients undergoing elective THA or TKA who received rivaroxaban 10 mg daily for the first 5 postoperative days. Patients were then randomized to receive either continued rivaroxaban or aspirin 81 mg daily for an additional 30 days (THA) or 9 days (TKA). The study demonstrated that extended aspirin was noninferior to rivaroxaban (symptomatic VTE 0.64% vs 0.70%, P<0.001 for noninferiority), with identical major bleeding rates (0.47% vs 0.29%), firmly validating aspirin step-down therapy.
• CRISTAL Trial Findings: The CRISTAL trial (Sidhu et al., JAMA 2022) challenged immediate aspirin monotherapy. In a cluster-randomized crossover trial of 9,711 patients across 31 hospitals, aspirin 100 mg daily administered from postoperative day 1 was compared directly to enoxaparin 40 mg daily. Aspirin failed noninferiority and was statistically inferior to enoxaparin for 90-day symptomatic VTE (3.45% in the aspirin group vs 1.82% in the enoxaparin group, P=0.007). Crucially, this difference was driven entirely by below-knee distal DVT in total knee arthroplasty patients (2.51% vs 1.10%), with no difference in pulmonary embolism (0.47% vs 0.35%) or all-cause mortality.
• Current Clinical Synthesis: Contemporary practice synthesizes these trials into a risk-stratified algorithm: standard-risk elective joint arthroplasty patients can safely receive multimodal prophylaxis with early mobilization, continuous mechanical compression, and low-dose aspirin, while high-risk patients (prior VTE, active malignancy, morbid obesity BMI >40 kg/m², hypercoagulable disorders) or TKA patients with prolonged tourniquet times benefit from an initial course of potent anticoagulation (LMWH or DOAC) before transitioning to aspirin.

Thromboprophylaxis in Musculoskeletal Trauma: The PREVENT CLOT Trial

For decades, low-molecular-weight heparin was considered the mandatory standard of care in fracture surgery because of perceived extreme thrombotic risk. The landmark PREVENT CLOT trial (Major Extremity Trauma Research Consortium [METRC], O’Toole et al., NEJM 2023) revolutionized trauma thromboprophylaxis. In 12,211 adult patients with extremity fractures treated operatively or pelvic/acetabular fractures, patients were randomized to aspirin 81 mg twice daily or enoxaparin 30 mg twice daily. The primary outcome of 90-day all-cause mortality occurred in 0.78% of the aspirin group compared to 0.73% of the enoxaparin group (P<0.001 for noninferiority). Pulmonary embolism occurred in 1.49% of both groups. Although deep vein thrombosis was slightly higher with aspirin (2.51% vs 1.71%), bleeding complications and wound infections were identical, providing definitive evidence that aspirin is a safe, effective, and accessible thromboprophylactic agent in musculoskeletal trauma.

Routine Ultrasound Screening: Overtreatment vs. True Benefit

Both the American Academy of Orthopaedic Surgeons (AAOS) and American College of Chest Physicians (ACCP) strongly recommend against routine screening duplex ultrasonography in asymptomatic patients following major orthopaedic surgery. While screening identifies non-propagating subclinical muscular and calf clots, treating these findings with therapeutic anticoagulation triples the risk of major surgical wound hematoma, persistent drainage, and reoperation, without providing any demonstrable reduction in symptomatic PE or patient mortality.

13. Evidence-Based Synthesis

Modern clinical decision-making is grounded in high-quality randomized controlled trials and prospective registry analyses, corroborated by seminal biomechanical and anatomical descriptions.

14. References

• Major Extremity Trauma Research Consortium (METRC), O’Toole RV, Stein DM et al. Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture. N Engl J Med. 2023. doi:10.1056/NEJMoa2205973 [Level I: Randomized Controlled Trial]
• Anderson DR, Dunbar M, Murnaghan J et al. Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. N Engl J Med. 2018. doi:10.1056/NEJMoa1712746 [Level I: Randomized Controlled Trial]
• CRISTAL Study Group, Sidhu VS, Kelly TL et al. Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial. JAMA. 2022. doi:10.1001/jama.2022.13416 [Level I: Randomized Controlled Trial]
• Eriksson BI, Borris LC, Friedman RJ et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008. doi:10.1056/NEJMoa0800374 [Level I: Randomized Controlled Trial]
• Lassen MR, Raskob GE, Gallus A et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010. doi:10.1016/S0140-6736(09)62125-5 [Level I: Randomized Controlled Trial]
• Falck-Ytter Y, Francis CW, Johanson NA et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012. doi:10.1378/chest.11-2404 [Level V: Clinical Practice Guideline]

15. Master Class Pro-Tip

The greatest error in orthopaedic thromboprophylaxis is treating the coagulation cascade in isolation while ignoring the surgical wound. A tense, leaking hematoma following joint replacement or major trauma transforms a clean surgical incision into a catastrophic periprosthetic joint infection (PJI) within days. In standard-risk elective joint arthroplasty, the combination of aggressive intraoperative hemostasis, tranexamic acid (TXA), rapid mechanical intermittent pneumatic compression started before extubation, day-of-surgery mobilization, and low-dose aspirin delivers an optimal balance: virtually eliminating fatal pulmonary embolism while safeguarding the delicate surgical wound. If an operative incision continues to drain beyond postoperative day 3, pause chemical anticoagulation immediately, maintain continuous bilateral IPC devices, inspect the joint, and remember: you can successfully treat an early DVT with anticoagulation, but an infected total joint replacement requires multiple major revision surgeries.

Master Class Surgical Pearl: Multimodal Thromboprophylaxis & Wound Hemostasis